Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Executive Summary

AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.

You may also be interested in...



AstraZeneca’s Oncology Strategy Yields Victories

The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.

Merck: It’s Not Just Keytruda Driving Future Growth

The company will depend on Keytruda for growth after spinning out some franchises, but executives argued during its Q4 earnings call that there will be much more to Merck than the cancer blockbuster.

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel